| Title article: | COMPARATIVE CHARACTERISTICS OF THE INFLUENCE OF METFORMIN, VILDAGLIPTIN AND NEW CYANOTHIOACETAMIDE DERIVATIVES ON THE COURSE OF EXPERIMENTAL METABOLIC SYNDROME WITH DEXAMETHASONE LOAD |
|---|---|
| Section: | The original article |
| Authors: | Elena Sergeevna Ketova;Elena Yuryevna Bibik;Anna Vadimovna Myazina;Krivokolysko Sergey Gennadievich;Valentina Yakovlevna Konovodova |
| Full article in PDF: | скачать |
This paper presents the results of a comparative assessment of the effect of metformin, vildagliptide and new cyanothioacetamide derivatives on the course of experimental metabolic syndrome with dexamethasone load in Wistar rats. It was revealed that metformin has the most pronounced hypoglycemic properties as a pharmacotherapy for experimental metabolic disorders. The new compound AZ-383 and vildagliptin were found to have the same ability to lower blood glucose. All compounds from a number of new cyanothioacetamide derivatives showed significantly pronounced hypolipidemic, hepatoprotective effects, the ability to reduce animal body weight in comparison with metformin and vildagliptin, which is an important aspect of pharmacocorrection of comorbid pathology, combining disorders of carbohydrate and lipid metabolism, obesity and liver damage.
Text article:

